Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Anemia, Refractory, with Excess of Blasts × Bortezomib × 30 days × Clear all

Sponsor

Conditions

Multiple Myeloma 25 Immunoglobulin Light-chain Amyloidosis 5 Paraproteinemias 2 Neoplasms, Plasma Cell 2 beta-Thalassemia 1 Waldenstrom Macroglobulinemia 1 Thalassemia 1 Renal Insufficiency 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Multi-centric Castleman's Disease 1 Macular dystrophy, corneal type 1 1 Lymphoproliferative Disorders 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Lymphadenopathy 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 HIV Infections 1 Anemia, Sickle Cell 1 Amyloidosis 1

Interventions

fludarabine 4 Mycophenolic Acid 4 Cyclophosphamide 4 fludarabine phosphate 3 Whole-Body Irradiation 3 Azacitidine 3 venetoclax 2 Vorinostat 2 Tacrolimus 2 Specimen Handling 2 Biopsy 2 decitabine and cedazuridine drug combination 1 cedazuridine 1 TAK-243 1 Stem Cell Transplantation 1 Sirolimus 1 Peripheral Blood Stem Cell Transplantation 1 Mesna 1 Melphalan 1 Lenalidomide 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Cyclosporins 1 Cyclosporine 1 Clofarabine 1 Busulfan 1 Bone Marrow Transplantation 1 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡